REGENXBIO Inc. (RGNX) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $9.14 (+1.90%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 5, 2026 | Judah Frommer | Morgan Stanley | $17.00 | +86.0% |
| Feb 10, 2026 | Brian Skorney | Robert W. Baird | $27.00 | +195.4% |
| Jan 29, 2026 | Yi Chen | H.C. Wainwright | $34.00 | +272.0% |
| Dec 15, 2025 | Mani Foroohar | Leerink Partners | $20.00 | +118.8% |
| Jan 7, 2025 | Luca Issi | RBC Capital | $30.00 | +228.2% |
| Nov 15, 2024 | Judah Frommer | Morgan Stanley | $22.00 | +140.7% |
| Oct 10, 2024 | Danielle Brill | Raymond James | $18.00 | +96.9% |
| Sep 5, 2024 | Yi Chen | H.C. Wainwright | $39.00 | +326.7% |
| Jun 24, 2024 | Annabel Samimy | Stifel Nicolaus | $40.00 | +337.6% |
| Jun 7, 2024 | Paul Choi | Goldman Sachs | $38.00 | +315.8% |
| May 15, 2024 | Yi Chen | H.C. Wainwright | $38.00 | +315.8% |
| Mar 11, 2024 | Yi Chen | H.C. Wainwright | $36.00 | +293.9% |
| Mar 8, 2024 | Luca Issi | RBC Capital | $35.00 | +282.9% |
Top Analysts Covering RGNX
RGNX vs Sector & Market
| Metric | RGNX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.09 | 2.24 | 2.41 |
| Analyst Count | 11 | 8 | 18 |
| Target Upside | +181.7% | +1150.0% | +14.9% |
| P/E Ratio | -2.32 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $163M | $252M | $378M | 8 |
| 2027-03-31 | $7M | $35M | $43M | 3 |
| 2027-06-30 | $10M | $50M | $61M | 3 |
| 2027-09-30 | $18M | $90M | $110M | 3 |
| 2027-12-31 | $9M | $42M | $51M | 3 |
| 2028-03-31 | $17M | $83M | $102M | 2 |
| 2028-06-30 | $18M | $86M | $105M | 2 |
| 2028-09-30 | $18M | $88M | $107M | 2 |
| 2028-12-31 | $19M | $94M | $115M | 2 |
| 2029-12-31 | $431M | $740M | $1.19B | 2 |
| 2030-12-31 | $580M | $996M | $1.60B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-4.48 | $-2.15 | $1.48 | 8 |
| 2027-03-31 | $-1.37 | $-1.06 | $0.04 | 1 |
| 2027-06-30 | $-1.16 | $-0.90 | $0.03 | 1 |
| 2027-09-30 | $-0.13 | $-0.10 | $0.00 | 1 |
| 2027-12-31 | $-1.46 | $-1.14 | $0.04 | 1 |
| 2028-03-31 | $-0.12 | $-0.09 | $0.00 | 2 |
| 2028-06-30 | $-0.17 | $-0.13 | $0.00 | 2 |
| 2028-09-30 | $-0.15 | $-0.12 | $0.00 | 2 |
| 2028-12-31 | $-0.17 | $-0.13 | $0.00 | 2 |
| 2029-12-31 | $1.05 | $2.30 | $4.11 | 1 |
| 2030-12-31 | $2.88 | $6.30 | $11.25 | 1 |
Frequently Asked Questions
What is the analyst consensus for RGNX?
The consensus among 11 analysts covering REGENXBIO Inc. (RGNX) is Buy with an average price target of $26.00.
What is the highest price target for RGNX?
The highest price target for RGNX is $40.00, set by Annabel Samimy at Stifel Nicolaus on 2024-06-24.
What is the lowest price target for RGNX?
The lowest price target for RGNX is $17.00, set by Judah Frommer at Morgan Stanley on 2026-03-05.
How many analysts cover RGNX?
11 analysts have issued ratings for REGENXBIO Inc. in the past 12 months.
Is RGNX a buy or sell right now?
Based on 11 analyst ratings, RGNX has a consensus rating of Buy (2.09/5) with a +181.7% upside to the consensus target of $26.00.
What are the earnings estimates for RGNX?
Analysts estimate RGNX will report EPS of $-2.15 for the period ending 2026-12-31, with revenue estimated at $252M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.